Skip to main content
. 2017 Jun 28;8(37):61901–61916. doi: 10.18632/oncotarget.18717

Figure 4. Expression level of astrocyte-elevated gene-1 affects disease progression and survival.

Figure 4

(A) Progression-free survival plots (PFS) for patients with low and high levels of astrocyte-elevated gene-1 (AEG-1) expression are illustrated. PFS for patients with low AEG-1 expression was significantly longer (low vs. high, 11.7 vs. 6.1 months; P = 0.006, log rank test). (B) Overall survival analysis (OS) for patients with low and high AEG-1 expression levels. OS for patients with low AEG-1 expression was significantly longer (low vs. high, 48.0 vs. 25.0 months; P = 0.005, log rank test).